EXEL

Exelixis, Inc. Press Releases

$1.33
*  
0.02
1.48%
Get EXEL Alerts
*Delayed - data as of Dec. 19, 2014  -  Find a broker to begin trading EXEL now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Exelixis’ Collaborator Genentech Files New Drug Application for the Combination of Cobimetinib and Vemurafenib for the Treatment of Patients With BRAF V600 Mutation-Positive Advanced Melanoma
12/15/2014 1:00:00 AM - Business Wire
▼-5.00 % Price Change since this news event. The Volume Ratio is 1.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Exelixis Announces Results from the COMET-2 Pivotal Phase 3 Trial of Cabozantinib in Men With Metastatic Castration-Resistant Prostate Cancer
12/1/2014 8:00:00 AM - Business Wire
▼-19.88 % Price Change since this news event. The Volume Ratio is 9.47.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Exelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2
11/25/2014 4:05:00 PM - Business Wire


Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888 and Vemurafenib
11/16/2014 4:20:00 AM - Business Wire


Exelixis to Present at the Stifel 2014 Healthcare Conference on Tuesday, November 18
11/11/2014 4:40:00 PM - Business Wire
▼-24.86 % Price Change since this news event. The Volume Ratio is 1.05.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic Renal Cell Carcinoma
11/6/2014 6:00:00 AM - Business Wire
▼-24.00 % Price Change since this news event. The Volume Ratio is 0.67.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Exelixis Announces Positive Top-Line Results From a Phase 2 Trial of Cabozantinib and Erlotinib in Patients With EGFR Wild-Type Non-Small Cell Lung Cancer
11/4/2014 4:14:00 PM - Business Wire
▼-19.39 % Price Change since this news event. The Volume Ratio is 3.18.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Exelixis Announces Third Quarter 2014 Financial Results and Provides Corporate Update
11/4/2014 4:13:00 PM - Business Wire
▼-19.39 % Price Change since this news event. The Volume Ratio is 3.23.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Exelixis to Release Third Quarter 2014 Financial Results on Tuesday, November 4, 2014
10/14/2014 4:12:00 PM - Business Wire
▼-12.50 % Price Change since this news event. The Volume Ratio is 0.86.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Exelixis Announces Positive Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma
9/29/2014 3:00:00 AM - Business Wire